logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Psychiatry drugs

    FiltersReset Filters
    27 results

    • abilify

      (ARIPIPRAZOLE)
      Otsuka America Pharmaceutical, Inc.
      Usage: ABILIFY (aripiprazole) is indicated for the treatment of schizophrenia, acute manic and mixed episodes associated with Bipolar I Disorder, adjunctive treatment of major depressive disorder, irritability associated with autistic disorder, and treatment of Tourette's disorder.

    • abilify asimtufii

      (Aripiprazole)
      Otsuka America Pharmaceutical, Inc
      Usage: ABILIFY ASIMTUFII is indicated for the treatment of schizophrenia in adults and for maintenance monotherapy of bipolar I disorder in adults.

    • abilify maintena

      (aripiprazole)
      Otsuka America Pharmaceutical, Inc.
      Usage: ABILIFY MAINTENA (aripiprazole) is indicated for the treatment of schizophrenia and as maintenance monotherapy for bipolar I disorder in adults.

    • abilify mycite

      (ARIPIPRAZOLE)
      Otsuka America Pharmaceutical, Inc.
      Usage: ABILIFY MYCITE is indicated for treating adults with schizophrenia, bipolar I disorder (including both acute and maintenance phases), and as adjunctive therapy for Major Depressive Disorder. It features an Ingestible Event Marker (IEM) sensor to track medication ingestion.

    • aplenzin

      (bupropion hydrobromide)
      Bausch Health US, LLC
      Usage: APLENZIN (bupropion hydrobromide) is indicated for treating major depressive disorder (MDD) and for the prevention of seasonal major depressive episodes in patients with seasonal affective disorder (SAD). Efficacy has been demonstrated in multiple controlled trials for both indications.

    • aristada

      (aripiprazole lauroxil)
      Alkermes, Inc.
      Usage: ARISTADA is indicated for the treatment of schizophrenia in adults.

    • azstarys

      (Serdexmethylphenidate and Dexmethylphenidate)
      Corium, LLC.
      Usage: AZSTARYS is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older.

    • barhemsys

      (Amisulpride)
      Acacia Pharma Ltd
      Usage: BARHEMSYS® is indicated for adults to prevent and treat postoperative nausea and vomiting (PONV), either alone or in combination with a different class antiemetic, and for patients who have or have not received prior antiemetic prophylaxis.

    • caplyta

      (lumateperone)
      Intra-Cellular Therapies, Inc
      Usage: CAPLYTA is indicated for treating schizophrenia in adults and for depressive episodes associated with bipolar I or II disorder in adults, both as monotherapy and as adjunctive therapy with lithium or valproate.

    • cobenfy

      (xanomeline and trospium chloride)
      E.R. Squibb & Sons, L.L.C.
      Usage: COBENFY is indicated for the treatment of schizophrenia in adults.